Amid rising global cancer rates and a shortage of pathology staff, Taiwan-based AetherAI says its FDA- and IVDR-certified digital pathology platform could ease diagnostic bottlenecks worldwide by enabling integrated AI tools and automated workflows, potentially accelerating access to faster, scalable cancer diagnostics across hospitals, healthcare systems, and clinics globally.